{"id":"https://openalex.org/W4361816348","doi":"https://doi.org/10.1158/1078-0432.c.6524427","title":"Data from Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes","display_name":"Data from Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes","publication_year":2023,"publication_date":"2023-03-31","ids":{"openalex":"https://openalex.org/W4361816348","doi":"https://doi.org/10.1158/1078-0432.c.6524427"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.c.6524427","doi":"https://doi.org/10.1158/1078-0432.c.6524427","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.c.6524427","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"other","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"http://dx.doi.org/10.1158/1078-0432.c.6524427","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5066422836","display_name":"Morganna Freeman-Keller","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Morganna Freeman-Keller","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101832668","display_name":"Young\u2010Chul Kim","orcid":"https://orcid.org/0000-0001-7019-7687","observed_orcids":["https://orcid.org/0000-0001-7019-7687"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Youngchul Kim","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023605565","display_name":"Heather Cronin","orcid":"https://orcid.org/0000-0001-9204-7241","observed_orcids":["https://orcid.org/0000-0001-9204-7241"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Heather Cronin","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006339007","display_name":"Allison L. Richards","orcid":"https://orcid.org/0000-0003-2312-2302","observed_orcids":["https://orcid.org/0000-0003-2312-2302"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Allison Richards","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026672076","display_name":"Geoffrey Thomas Gibney","orcid":"https://orcid.org/0000-0002-5401-8498","observed_orcids":["https://orcid.org/0000-0002-5401-8498"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Geoffrey Gibney","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5047177507","display_name":"Jeffrey S. Weber","orcid":"https://orcid.org/0000-0002-4962-2957","observed_orcids":["https://orcid.org/0000-0002-4962-2957"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jeffrey S. Weber","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/nivolumab","display_name":"nivolumab","score":0.9900000095367432},{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.8980000019073486},{"id":"https://openalex.org/keywords/metastatic-melanoma","display_name":"metastatic melanoma","score":0.9380000233650208},{"id":"https://openalex.org/keywords/cutaneous-adverse-effects","display_name":"cutaneous adverse events","score":0.7020000219345093},{"id":"https://openalex.org/keywords/skin-rash","display_name":"rash","score":0.9390000104904175},{"id":"https://openalex.org/keywords/vitiligo","display_name":"vitiligo","score":0.996999979019165},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.7950000166893005},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.6819999814033508},{"id":"https://openalex.org/keywords/peptide-vaccine","display_name":"peptide vaccine","score":0.8309999704360962},{"id":"https://openalex.org/keywords/resected-melanoma","display_name":"resected melanoma","score":0.7990000247955322},{"id":"https://openalex.org/keywords/unresectable-melanoma","display_name":"unresectable melanoma","score":0.8840000033378601},{"id":"https://openalex.org/keywords/colitis","display_name":"colitis","score":0.5820000171661377},{"id":"https://openalex.org/keywords/endocrine-disorders","display_name":"endocrine disorders","score":0.8740000128746033},{"id":"https://openalex.org/keywords/pneumonitis","display_name":"pneumonitis","score":0.9919999837875366},{"id":"https://openalex.org/keywords/prognostic-factors","display_name":"prognostic factors","score":0.6890000104904175}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8411206603050232},{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.7698146104812622},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6442491412162781},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6190694570541382},{"id":"https://openalex.org/C2778570526","wikidata":"https://www.wikidata.org/wiki/Q653197","display_name":"Rash","level":2,"score":0.602627158164978},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.5554133057594299},{"id":"https://openalex.org/C207103383","wikidata":"https://www.wikidata.org/wiki/Q3930246","display_name":"Hazard ratio","level":3,"score":0.5348621010780334},{"id":"https://openalex.org/C50382708","wikidata":"https://www.wikidata.org/wiki/Q223218","display_name":"Proportional hazards model","level":2,"score":0.49812912940979004},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.32528966665267944},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.1651650369167328},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.07447916269302368}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1078-0432.c.6524427","doi":"https://doi.org/10.1158/1078-0432.c.6524427","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.c.6524427","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.c.6524427","doi":"https://doi.org/10.1158/1078-0432.c.6524427","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.c.6524427","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2179179825","https://openalex.org/W2605154526","https://openalex.org/W3001173873","https://openalex.org/W2905314444","https://openalex.org/W4415898981","https://openalex.org/W3011243232","https://openalex.org/W4402019165","https://openalex.org/W2904477283","https://openalex.org/W4379338431","https://openalex.org/W2549481046"],"abstract_inverted_index":{"Abstract":[0],"Purpose:":[1],"Retrospective":[2],"analysis":[3,77],"of":[4,66,97,101,108,111,152],"irAEs":[5,115,237,244],"in":[6,88,92,106,131,165,216,250,262],"melanoma":[7,251],"patients":[8,19,109,148,166,217,252],"treated":[9,24,253],"with":[10,25,40,149,184,211,218,235,247,254],"nivolumab.":[11],"Experimental":[12],"Design:":[13],"Data":[14],"were":[15,71,104,116,233],"pooled":[16],"from":[17],"148":[18],"(33":[20],"resected,":[21],"115":[22],"unresectable)":[23],"nivolumab":[26,31,51],"plus":[27],"peptide":[28],"vaccine":[29],"or":[30,43,95,170,240],"alone":[32,52],"every":[33,53],"2":[34,59,124,134],"weeks":[35,55],"for":[36,56],"12":[37,54],"weeks.":[38],"Patients":[39],"stable":[41],"disease":[42,220],"regression":[44],"received":[45],"an":[46],"additional":[47,60],"12-week":[48,74],"cycle,":[49],"then":[50],"up":[57],"to":[58],"years.":[61],"Frequency,":[62],"grade,":[63],"and":[64,133,160,196,207,224,256],"characteristics":[65],"immune-related":[67],"adverse":[68],"events":[69,173],"(irAE)":[70],"analyzed.":[72],"A":[73,140],"landmark":[75],"survival":[76,90,231,249],"using":[78],"a":[79],"multivariate":[80],"time-dependent":[81],"Cox":[82],"proportional":[83],"hazard":[84],"model":[85],"assessed":[86],"difference":[87,144],"overall":[89],"(OS)":[91],"the":[93],"presence":[94],"absence":[96],"irAEs.":[98],"Results:":[99],"IrAEs":[100],"any":[102,150],"grade":[103,121,128,137,151],"observed":[105],"68.2%":[107],"(101":[110],"148).":[112],"Grade":[113],"III/IV":[114],"infrequent:":[117],"3":[118],"(2%)":[119],"had":[120,126,136],"III":[122,129,138],"rash,":[123],"(1.35%)":[125,135],"asymptomatic":[127],"elevation":[130],"amylase/lipase,":[132],"colitis.":[139],"statistically":[141,180,212],"significant":[142,181,213,230],"OS":[143,161,182,214],"was":[145,163],"noted":[146,164],"among":[147],"irAE":[153,172],"versus":[154],"those":[155],"without":[156],"(P":[157,174,198,221],"\u2264":[158,175],"0.001),":[159],"benefit":[162,258],"who":[167],"reported":[168],"three":[169],"more":[171],"0.001).":[176],"Subset":[177],"analyses":[178],"showed":[179],"differences":[183,215,232],"rash":[185],"[P":[186],"=":[187,199,222,226],"0.001;":[188],"HR,":[189,201],"0.423;":[190],"95%":[191,203],"confidence":[192],"interval":[193],"(CI),":[194],"0.243\u20130.735]":[195],"vitiligo":[197,208],"0.012;":[200],"0.184;":[202],"CI,":[204],"0.036\u20130.94).":[205],"Rash":[206],"also":[209],"correlated":[210],"metastatic":[219],"0.004":[223],"P":[225],"0.028,":[227],"respectively).":[228],"No":[229],"seen":[234],"other":[236],"(endocrinopathies,":[238],"colitis,":[239],"pneumonitis).":[241],"Conclusions:":[242],"Cutaneous":[243],"are":[245],"associated":[246],"improved":[248],"nivolumab,":[255],"clinical":[257],"should":[259],"be":[260],"validated":[261],"larger":[263],"prospective":[264],"analyses.":[265],"Clin":[266],"Cancer":[267],"Res;":[268],"22(4);":[269],"886\u201394.":[270],"\u00a92015":[271],"AACR.":[272]},"counts_by_year":[],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2023-04-05T00:00:00"}